Skip to main content
OpenTrials
Completed

NCT Number: NCT01779375

RISE Pediatric Medication Study

The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Pediatric participants (ages 10-19) will be randomized to one of the following treatment regimens: (1) metformin alone or (2) early intensive treatment with basal insulin glargine followed by metformin.

The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

10 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Childrens Hospital Colorado, Denver, Colorado, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Fasting plasma glucose ≥90 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus laboratory-based HbA1c ≤8.0% if treatment naïve. There is no upper limit for the 2-hour glucose on OGTT. In those taking metformin laboratory-based HbA1c must be ≤7.5% if on metformin for <3 months and ≤7.0% if on metformin for 3-6 months.
  • Age 10-19 years
  • Pubertal development Tanner stage >1 as defined by breast stage >1 in girls, and testes >3 cc's in boys.
  • Body mass index (BMI) ≥85th percentile but ≤50 kg/m2
  • Self-reported diabetes <6 months in duration
  • Treatment with metformin for <6 months preceding screening

Exclusion criteria

  • Underlying disease likely to limit life span and/or increase risk of intervention or an underlying condition that is likely to limit ability to participate in outcomes assessment
  • An underlying disease that affects glucose metabolism other than type 2 diabetes mellitus
  • Taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications
  • Treatment with insulin for >1 week preceding screening
  • Active infections
  • Renal disease (serum creatinine >1.2 mg/dl) or serum potassium abnormality (<3.4 or >5.5 mmol/l)
  • Anemia (hemoglobin <11 g/dl in girls, <12 g/dl in boys) or known coagulopathy
  • Cardiovascular disease, including uncontrolled hypertension defined as average systolic or diastolic blood pressure > 99 percentile for age or >135/90, despite adequately prescribed antihypertensive medications. Participants must be able to safely tolerate administration of intravenous fluids required during clamp studies.
  • History of conditions that may be precipitated or exacerbated by a study drug:
  • Serum alanine transaminase (ALT) more than 3 times the upper limit of normal
  • Excessive alcohol intake
  • Sub-optimally treated thyroid disease
  • Conditions or behaviors likely to affect the conduct of the RISE Study
  • Participant and/or parents unable or unwilling to give informed consent
  • Participant and/or parents unable to adequately communicate with clinic staff
  • Another household member is a participant or staff member in RISE
  • Current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE
  • Weight loss of ≥5% of body weight in the past 3 months for any reason other than post-partum weight loss. Participants taking weight loss drugs or using preparations taken for intended weight loss are excluded.
  • Likely to move away from participating clinics in next 2 years
  • Current (or anticipated) pregnancy and lactation.
  • A pregnancy that was completed less than 6 months prior to screening.
  • Breast feeding within 6 months prior to screening.
  • Women of childbearing potential who are unwilling to use adequate contraception
  • Major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE
  • Additional conditions may serve as criteria for exclusion at the discretion of the local site.

Treatment and study plan

metformin

Drug

Other names: Glucophage

Glargine

Drug

Other names: Insulin glargine, Lantus

Primary outcomes

  1. ß-cell Response Measured by Hyperglycemic Clamp

    Time frame: 3-months after medication washout (Month 15)

    Clamp measures of ß-cell response, co-primary outcomes

  2. M/I

    Time frame: 3-months after a medication washout

    Clamp measure of insulin sensitivity

Secondary outcomes

  1. ACPRg

    Time frame: 3-months after a medication washout

    First phase response

  2. ß-cell Function Measured by Hyperglycemic Clamp Techniques at M12

    Time frame: End of active intervention (Month 12).

    Participants had 12-months of active therapy. Secondary results at the end of active intervention.

  3. Clamp Measure of Insulin Sensitivity

    Time frame: End of active intervention (Month 12)

    Participants had 12-months of active therapy. Secondary results at the end of active intervention.

Other outcomes

  1. OGTT Measures of ß-cell Function and Glucose Tolerance

    Time frame: After 12 months of active treatment, and 3 and 9 months of washout

    Measures derived the OGTT at the end of the 12 month active intervention period, and following a 3-month and 9-month washout.

Sponsors and collaborators

Lead sponsor

RISE Study Group

Network

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Official study title

Restoring Insulin Secretion Pediatric Medication Study

Acronym: RISE Peds

Important dates

Study start
2013
Primary completion
2017
Study completion
2018
First posted
Jan 30, 2013
Registry last updated
Apr 14, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.